Immune Response BioPharma, Inc.

Immune Response BioPharma, Inc. Files for Orphan Designation of Blockbuster RA Vaccine RAVAX for expanded use into the rare disease Juvenile Rheumatoid Arthritis.

Immune Response BioPharma, Inc. Files for Orphan Designation for Blockbuster Drug NeuroVax for Multiple Sclerosis

Immune Response BioPharma, Inc. Provides Business Update Sees Blockbuster MS Drug NeuroVax the Gold Standard of Care for MS and a Partnership by the end of Q1 2013

REMUNE Effectiveness Extends Years After Inoculation REMUNE Injected Patient Has 2 Healthy HIV Free Children Proving the Vaccine has Strong Immune Responses a Decade Later

Immune Response BioPharma, Inc. Sees First Year REMUNE Sales North of $1 Billion Dollars

Immune Response BioPharma, Inc. Review of Blockbuster RA Vaccine RAVAX Phase 2B 340 Patient Study Results Demonstrated a 50% Improvement in Patients Vaccinated with RAVAX.

Immune Response BioPharma, Inc. Provides Blockbuster RAVAX Phase III Study in RA Update With Inadequate Response to Humira or Enbrel now Available at www.immuneresponse.net

Immune Response BioPharma, Inc. Announces Formulation Changes to Blockbuster RA Drug RAVAX Adds 4th Peptide for Potent RA Vaccine

Immune Response BioPharma, Inc. Posts 1st Half 2012 Results Highlights include IRBP Granted U.S. Patent 8,053,197 for Auto-Immune Diseases & Plans for a Phase 2B NeuroVax Study and a Phase 3 RAVAX Study for RA.

Immune Response BioPharma, Inc. On the Move Plans Listing on German Exchanges to Fund Blockbuster MS Drug NeuroVax & Pipeline